In addition to uncovering a novel MDM2/c-Myc regulatory loop involved in oncogenesis, our study provides the rationale for the use of a newly discovered small molecule inhibitor MX69 for the treatment of MM. Here, MDM2 is linked to Miyoshi myopathy.